高盛发表报告指，药明生物(02269.HK) 上半年收入及经调整纯利均胜预期。期内收入较该行预期高出约3%，主要受惠于临床前项目需求强劲及中国业务加速增长。经调整毛利率由去年同期的45.6%扩张至48.4%，受惠于产能利用率提升、制造规模效益、持续效率改善，以及高利润率复杂项目贡献增加，惟部分被外汇逆风所抵销。毛利率扩张属结构性及可持续，而非一次性因素推动。该行指出，总在手未完成订单按年升24%至...
Source Link高盛发表报告指，药明生物(02269.HK) 上半年收入及经调整纯利均胜预期。期内收入较该行预期高出约3%，主要受惠于临床前项目需求强劲及中国业务加速增长。经调整毛利率由去年同期的45.6%扩张至48.4%，受惠于产能利用率提升、制造规模效益、持续效率改善，以及高利润率复杂项目贡献增加，惟部分被外汇逆风所抵销。毛利率扩张属结构性及可持续，而非一次性因素推动。该行指出，总在手未完成订单按年升24%至...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.